73  Total SME IPOs listed in 2025

3,196.85 Crs.  Total funds raised in 2025

49  SME IPOs listed with Gain in 2025

24  SME IPOs listed with loss in 2025

73  Total SME IPOs listed in 2025

3196.85 Crs.  Total funds raised in 2025

49  SME IPOs listed with Gain in 2025

24  SME IPOs listed with loss in 2025

73  Total SME IPOs listed in 2025

3196.85 Crs.  Total funds raised in 2025

49  SME IPOs listed with Gain in 2025

24  SME IPOs listed with loss in 2025

73  Total SME IPOs listed in 2025

3196.85 Crs.  Total funds raised in 2025

49  SME IPOs listed with Gain in 2025

24  SME IPOs listed with loss in 2025

Glenmark Life Sciences IPO (Glenmark Life Sciences Limited IPO) Detail

Glenmark Life Sciences Limited is an Pharmaceutical based company, located in Solapur, Glenmark Life Sciences Limited IPO size was 1513.60 Cr. and was issued at 720.00 per share. The share of Glenmark Life Sciences Limited were listed at 748.20 per share and are currently trading at 1006.10 per share.

Type :
Sub Sector : Developer And Manufacturer
MainBoard IPO

Financial Summary (at the time of ipo, on annualised basis)

Revenue :
1885.98 Cr.

PAT :
351.58 Cr.

Pricing Report

Issue Price :
720.00

Listing Price :
748.20

Current Market Price :
1006.10

Issue Price vs CMP :
286.1 (39.74%)

listing Price vs CMP :
257.9 (34.47%)

Performance Report (CAGR* wise)

CAGR : 9.09
-ve 0 6 9 12+
Above Average

*CAGR is calculated basis issue price at the time of IPO and Current Market Price without taking into Consideration Bonus/Right issue.

*Stock splits/Reverse Stock Split are adjusted in Issue price while calculating CAGR and current performance.

About Glenmark Life Sciences

Company Information
Glenmark Life Sciences Limited is a leading developer and manufacturer of high-value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes (Source: Frost & Sullivan Report). It also manufactures APIs for gastro-intestinal disorders, anti-infectives, and other therapeutic areas. The company's API portfolio includes specialized and profitable products, with niche and technically complex molecules that highlight its capability to expand into other high-value areas.
The company holds a strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS), and Adapalene (dermatology) (Source: Frost & Sullivan Report). Additionally, it has been expanding its services to include contract development and manufacturing operations (CDMO) for multinational and
Show More
Object of Issue
  • To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company
  • To finance capital expenditure requirements
  • To meet general corporate purposes

Glenmark Life Sciences MainBoard IPO Details (at the time of IPO)

IPO Type :
Book Building
IPO Date :
Aug, 2021
IPO Size :
1513.60 Cr.
IPO Subscription :
44.17 X     
PE Multiple :
25.09
Merchant Banker :
Bob Capital Markets Limited
Thinking of
Listing Your Business through
SME IPO?
We can Help!
Contact Us Today

See Other MainBoard IPOs in Solapur

Scoda Tubes Limited

  manufacturer of stainless-steel tubes and pipes

  Ahmedabad


Prostarm Info Systems Limited

  designing, manufacturing, and selling Energy Storage and Power Conditioning Equipment

  Mumbai


Aegis Vopak Terminals Limited

  Owns and operates storage terminals for liquefied petroleum gas (LPG)

  Surat


Leela Hotels - Schloss Bangalore Limited

  luxury hospitality company operating under "The Leela" brand in India

  New Delhi



Peer Companies Of This Sector

FAQs

Glenmark Life Sciences operates in Pharmaceutical and Developer And Manufacturer. The Issue is listed on BSE,NSE in Aug, 2021. Glenmark Life Sciences IPO size was 1513.60 Cr. with Issue price of 720.00 .

Merchant Banker(s) of Glenmark Life Sciences IPO: Bob Capital Markets Limited , Bofa Securities India Limited , Dam Capital Advisors Limited (Formerly Idfc Securities Limited) , Goldman Sachs (India) Securities Private Limited

Glenmark Life Sciences IPO subscription was 44.17 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.

Glenmark Life Sciences IPO listed at a listing price of 748.20 against the offer price of 720.00.

The current market price of Glenmark Life Sciences is 1006.10.

Services

IPO Advisory
IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Readiness
IPO Readiness
IPO Roadmap by improving Business Efficiencies, Financial Parameters and Corporate Structure to become IPO ready.
Fund Raising
Fund Raising
Fuelling a company's growth through Pre IPO Fund Raise, Private Equity, and Angel Investing.
SME : Business Scaling
SME Business Upscaling
Provide support to build a scalable SME business by unleashing the SME potential.
Post IPO Montoring
Post IPO Mentoring
Assisting with post IPO regulatory requirements and Performance Monitoring to achieve the milestone of Mainboard migration.

Thinking of
Listing Your Business through SME IPO?

We can help! Contact Us

Why Us?

  • Leading portal for IPOs
  • End to End Solutions
  • Known for Transparency